AmyriAD to Host a Key Opinion Leader Webinar on Alzheimer’s Disease Management

-Webinar to discuss investigational strategies to improve symptoms in Alzheimer’s disease patients – Friday, September 30th@ 11:15 a.m. EDT LOS ANGELES, Sept. 19, 2022 (GLOBE NEWSWIRE) — AmyriAD Therapeutics, a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease, today announced that it will host a key opinion leader (KOL)…

Pharma Company AmyriAD Steps into the Light with Phase III Symptom Relief Drug for Alzheimer’s Disease

-After starting up in stealth mode, AmyriAD is ready to debut its Phase 3 investigational drug to relieve Alzheimer’s symptoms. AmyriAD will be attending the Clinical Trials of Alzheimer’s Disease Conference as a Silver Sponsor. – November 10th, 2021 AmyriAD – a biopharmaceutical company led by the development strategist who introduced the cognition enhancing medication…